Table 2 Completed clinical trials with PD-1/PD-L1 inhibitors in TETs
From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
N | Intervention/Treatment | Phase | TC | Tm | DCR (%) (95%CI) | mPFS (95%CI) | mOS (months) | Primary endpoint | Identifier | Ref. & Year |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Pembrolizumab | II | 40 | 0 | 22.5(10.8–38.5) | 4.2(2.9–10.3) | 24.9 | ORR | NCT02364076 | Giaccone et al., 2018 [61] |
2 | Pembrolizumab | II | 26 | 7 | 28.6/19.2 | 6.1(5.3–6.9) | 14.5/NA | ORR | NCT02607631 | Cho et al., 2019 [62] |
3 | Avelumab | I | 1 | 7 | 57(NA) | NA | NA | DLT | NCT01772004 | Rajan et al., 2019 [63] |
4 | Nivolumab | II | 15 | 0 | 0(0–21.8) | 3.8(1.9–7.0) | NA | ORR | PRIMER study NCCH1505 | Katsuya et al., 2019 [64] |